ondasdechoque.org
PT-BR

Plantar heel pain / plantar fasciopathy · Randomized trial · 2006

Does one high-energy shockwave session help long-lasting heel pain?

In this trial, morning heel pain fell from about 7.5 to 3.9 out of 10 three months after one focused shockwave session. With a placebo session it fell from about 7.9 to 5.3. About 47% of treated people reached the study's success goal, vs 23% with placebo.

Helped more than placebo
adults with long-lasting heel pain
114
session, with a numbing injection
1
followed up
3 mo

Good to know: Funded by the device maker.

Kudo P, Dainty K, Clarfield M, et al. Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society, 2006 · Read the paper ↗

How this study worked

Focused shockwave58 peoplePlacebo56 peopleShockwaveSham
People were assigned by lot. One group had a sham: the same-looking treatment without the active waves. Each dot is one person.

What happened

Heel pain with the first steps in the morning

0–10 pain scale · start and three months after one session

StartAfter 3 months

Morning pain fell from about 7.5 to 3.9 out of 10 with shockwave and from about 7.9 to 5.3 with placebo.
Show the numbers
GroupPeopleStartAfter 3 months
Focused shockwave537.53.9
Placebo527.95.3

The treatment

Focused shockwave

Focused, 1 session

Focused wavesMeet at a focal zone below the skin
Sessions
1
Pulses
3,800 per session
Strength
0.36mJ/mm² positive energy at the top level; 0.64 total
Numbing
Local anaesthetic
Device
Dornier Epos Ultra
Everyone also got
No sport or pain medicines until the 6-week visit

Compared with: A placebo session: the same procedure, with a foam cushion blocking the shockwaves

Settings are what each study used, not a prescription.

This protocol among the library’s

Each dot is a group treated with shockwaves in a study in this library, at the midpoint when the paper gave a range. The dark dots are this study.

Energy, focused waves0.36 mJ/mm²

Of the other 29 groups: 27 lower, 1 the same, 1 higher.

Pulses per session3,800

Of the other 69 groups: 57 lower, 2 the same, 10 higher.

Sessions1

Of the other 78 groups: 13 the same, 65 higher.

Who took part

114 adults with pain in one heel for over 6 months after several treatments, at four Canadian sport-medicine and orthopaedic clinics.

hollow squares: no final score

Focused shockwave53 of 58 measured
Placebo52 of 56 measured
105 of 114 people (92%) had a final score.

Side effects

Pain during treatment · During the session
Focused shockwave46 of 58
Placebo5 of 56

Most felt pain during treatment despite the nerve block (79% vs 9% with placebo). Other effects, such as swelling or tingling, were few and similar in both groups.

All the numbers and the full appraisal
FROM THE FULL PAPER

The results, in numbers.

114 adults at four Canadian sport-medicine and orthopaedic clinics (randomized November 2000–December 2002) with unilateral plantar fasciitis for more than 6 months, morning first-steps pain >5 on VAS and Roles and Maudsley 3–4, after failed NSAIDs and at least two other conservative treatments. Mean age 51.1 versus 48.8 years; women 40/58 versus 33/56; mean heel-pain history 31.3 versus 27.1 months.

Focused ESWT (Epos Ultra)58randomized

People, one foot each (bilateral symptoms excluded). Assessed 58 at 3–5 days, 56 at 6 weeks, 53 at 3 months; withdrawals: pain intolerance at treatment, cancer diagnosis, 2 lost interest, 1 missed visit. Methods claim intention-to-treat, but Table 3 reports n=53.

Placebo (foam-blocked head)56randomized

People, one foot each. Assessed 56 at 3–5 days, 53 at 6 weeks, 52 at 3 months; 2 lost interest after 3–5 days, 1 missed the 6-week and 2 the 3-month visit. Table 3 reports n=52.

Morning first-steps pain (primary)1 reported outcome
01
Three months after the single session

Morning first-steps pain (primary)

VAS, pain during the first few minutes of walking in the morning VAS points (range not stated)

means
GroupnBaselineFollow-up
Focused ESWT (Epos Ultra)537.5 (SD 1.5)3.9 (SD 3.2)
Placebo (foam-blocked head)527.9 (SD 1.5)5.3 (SD 2.7)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp = 0.0124

Active ESWT versus placebo

Pain fell in both groups (within-group P<0.0001 each); the fall was larger with active treatment (between-group P=0.0124). The paper reports mean percentage improvements of 49.1% versus 33.3%.

Analysis details and source

Table 3 prints P<0.0001 beside the 3-month row, while the text and Discussion give 0.0124 for the between-group change; 0.0124 is kept as the comparison. No CI for the difference. Observed n 53 and 52.

Clinical success: >60% less morning pain1 reported outcome
02
Three months after the single session

Clinical success: >60% less morning pain

Clinical success, >60% improvement from baseline in first-steps VAS People

Focused ESWT (Epos Ultra)25 / 53
Placebo (foam-blocked head)12 / 52
REPORTED COMPARISON TESTp = 0.0099

Active ESWT versus placebo

25 of 53 (47%) versus 12 of 52 (23%) met the study definition of success at 3 months.

Analysis details and source

Methods say "at least 60%", Results ">60%". The abstract also claims a significant success difference at 6 weeks, but no 6-week data are shown.

Pain during normal daily activity1 reported outcome
03
Three months after the single session

Pain during normal daily activity

VAS pain during normal daily activity VAS points (range not stated)

means
GroupnBaselineFollow-up
Focused ESWT (Epos Ultra)536.2 (SD 2)3.7 (SD 3.1)
Placebo (foam-blocked head)526 (SD 2)4.4 (SD 2.5)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp = 0.0524

Active ESWT versus placebo

Both groups improved; the difference did not reach the 0.05 threshold (P=0.0524).

Analysis details and source

Authors describe this as marginal significance (P<0.10).

Pain during leisure or sport1 reported outcome
04
Three months after the single session

Pain during leisure or sport

VAS pain during leisure/sport activity VAS points (range not stated)

means
GroupnBaselineFollow-up
Focused ESWT (Epos Ultra)537.4 (SD 2.4)3.9 (SD 3.5)
Placebo (foam-blocked head)527.7 (SD 2.1)5.2 (SD 2.9)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp = 0.0904

Active ESWT versus placebo

Both groups improved; the between-group difference was not significant (P=0.0904).

Analysis details and source

Observed n 53 and 52; no CI.

Pain before going to bed1 reported outcome
05
Three months after the single session

Pain before going to bed

VAS pain prior to bed VAS points (range not stated)

means
GroupnBaselineFollow-up
Focused ESWT (Epos Ultra)536.2 (SD 2.4)3.9 (SD 3.3)
Placebo (foam-blocked head)526.5 (SD 2.5)4.9 (SD 2.6)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp = 0.0793

Active ESWT versus placebo

Both groups improved; the between-group difference was not significant (P=0.0793).

Analysis details and source

Observed n 53 and 52; no CI.

Roles and Maudsley excellent or good1 reported outcome
06
Three months after the single session

Roles and Maudsley excellent or good

Roles and Maudsley Score (patient self-assessment of pain and activity) People

Focused ESWT (Epos Ultra)23 / 53
Placebo (foam-blocked head)16 / 52
REPORTED COMPARISON TESTp = 0.0121

Active ESWT versus placebo

23 of 53 versus 16 of 52 rated their result excellent or good; everyone was fair or poor at baseline.

Analysis details and source

Secondary outcome; the test compares the score distribution, not only the excellent-good proportion.

AOFAS ankle–hindfoot total1 reported outcome
07
Three months after the single session

AOFAS ankle–hindfoot total

AOFAS ankle–hindfoot scale, total score Percent change from baseline

means
GroupnBaselineReported change
Focused ESWT (Epos Ultra)53—30.3 (SD 33.3)
Placebo (foam-blocked head)52—25.8 (SD 34.2)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp = 0.2927

Active ESWT versus placebo

Mean percentage change was similar between groups (P=0.2927). AOFAS pain-domain success (none or mild pain) was 27/53 versus 18/52 (P=0.0913).

Analysis details and source

Reported as % change (SD); a nonsignificant result does not show the treatments are equivalent.

SF-12 physical health1 reported outcome
08
Three months after the single session

SF-12 physical health

SF-12 Global Health Rating Scale, physical component Percent change from baseline

means
GroupnBaselineReported change
Focused ESWT (Epos Ultra)53—14.2 (SD 25.5)
Placebo (foam-blocked head)52—9.1 (SD 33.8)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp = 0.2229

Active ESWT versus placebo

No significant difference in physical (P=0.2229) or mental health change (6.8% versus 2.0%, P=0.7812); authors say the study was not powered for SF-12.

Analysis details and source

Mental component: 6.8 (SD 29.4) versus 2.0 (SD 19.1).

Pain threshold on palpation1 reported outcome
09
Three months after the single session

Pain threshold on palpation

Pressure threshold meter (Pain Diagnostics and Thermography) Pressure threshold (unit not stated)

means
GroupnBaselineFollow-up
Focused ESWT (Epos Ultra)535.7 (SD 2)7.2 (SD 2.5)
Placebo (foam-blocked head)526.2 (SD 2.5)6.3 (SD 2.3)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp = 0.0027

Active ESWT versus placebo

The tolerated pressure rose with active treatment and changed little with placebo (P=0.0027).

Analysis details and source

Higher values are read as less tenderness; the paper does not state the unit or direction explicitly.

Pain during treatment1 reported outcome
10
During the session

Pain during treatment

Patient report of pain during the session People

Focused ESWT (Epos Ultra)46 / 58
Placebo (foam-blocked head)5 / 56
REPORTED COMPARISON TESTp <0.0001

Active ESWT versus placebo

Despite the nerve block, 46 of 58 felt pain during active treatment versus 5 of 56 with placebo (Table 3: 79.3% versus 8.9%).

Analysis details and source

This difference can reveal allocation to patients.

Believed they received active treatment1 reported outcome
11
Immediately after the session

Believed they received active treatment

Blinding check immediately after treatment People

Focused ESWT (Epos Ultra)34 / 58
Placebo (foam-blocked head)13 / 56
REPORTED COMPARISON TESTp = 0.0007

Active ESWT versus placebo

34 active versus 13 placebo patients believed they had received shockwaves; 22 (37.9%) versus 33 (58.9%) did not know. The authors nevertheless conclude blinding worked as well as possible.

Analysis details and source

Denominators taken as all treated (58 and 56); percentages for "did not know" match these.

How treatment was delivered
Device and modality

Dornier Epos Ultra focused shockwave system, single session, ultrasound localization of the focal area, therapy head coupled on the medial heel; patients prone (44.7%) or on their side (55.3%).

Dose

Energy ramped over levels 1–6 (about 50 shocks each, 60 to 210 shocks/min), then about 3,500 shocks at level 7: 0.36 mJ/mm² positive energy-flux density (ED+), stated as 0.64 mJ/mm² total ED, 240 shocks/min. About 3,800 shocks in all, approximated total 1,300 mJ/mm² (ED+) or 2,330 mJ/mm² (ED).

Anaesthesia

Medial calcaneal nerve block with 5 mL of 1% Xylocaine 15–20 minutes before the procedure, in both groups.

Placebo

Identical procedure, but a thin foam cushion with ultrasound gel on the therapy head stopped shock waves entering the foot; the cushion was fitted before the patient entered the room and replaced each session.

Aftercare and follow-up

No athletic activity or pain medication until the 6-week visit; medication diaries kept. Blinded assessments at 3–5 days, 6 weeks and 3 months, then unblinding; placebo patients with persisting symptoms were offered active treatment. 6- and 12-month and crossover data were pending analysis.

HARMS & TOLERABILITY

Adverse events other than pain were few and, by Fisher tests, did not differ through 3 months: edema 3.5% versus 1.8%, paresthesia 1.8% versus 0, peripheral neuritis 1.8% versus 0 (resolved), back pain 1.8% versus 0 and pruritus in one placebo patient (both judged unrelated); pain after treatment 14% versus 27.3%. Pain during treatment was 79.3% versus 8.9%. Table 3 gives percentages without counts. All sites received research grants from Dornier MedTech America, the device maker.

LIMITS OF THE ANALYSIS

Author-reported: results apply only to the device settings used; the trial was not powered for SF-12; improvement with placebo may reflect natural history or placebo response.

Extractor interpretation: pain during active treatment (79.3% versus 8.9%) and the significant blinding-guess difference make patient unblinding plausible for a self-reported primary outcome.

Reporting inconsistencies: Table 3 prints P<0.0001 for the primary comparison while the text gives P=0.0124; the abstract claims a 6-week success difference without shown data; intention-to-treat is stated but Table 3 uses the 53 and 52 observed; the sample-size sentence is garbled ("should be #13").

Extractor interpretation: blinded comparison ends at 3 months; later and crossover results were pending. Device-maker funding of all sites and overlap with the earlier pivotal trial (Theodore 2004, ref. 11, with shared authors) are relevant context.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • Author-reported: results apply only to the device settings used; the trial was not powered for SF-12; improvement with placebo may reflect natural history or placebo response.
  • Extractor interpretation: pain during active treatment (79.3% versus 8.9%) and the significant blinding-guess difference make patient unblinding plausible for a self-reported primary outcome.
  • Reporting inconsistencies: Table 3 prints P<0.0001 for the primary comparison while the text gives P=0.0124; the abstract claims a 6-week success difference without shown data; intention-to-treat is stated but Table 3 uses the 53 and 52 observed; the sample-size sentence is garbled ("should be #13").
  • Extractor interpretation: blinded comparison ends at 3 months; later and crossover results were pending. Device-maker funding of all sites and overlap with the earlier pivotal trial (Theodore 2004, ref. 11, with shared authors) are relevant context.
Research review

Source-linked critical reading

Placebo-controlled double-blind randomized trial

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Study design

Multicentre, randomized, placebo-controlled, double-blind confirmatory trial at four Canadian sites, with a randomization scheme from Biostat International in sealed opaque envelopes and blinded assessors. 114 randomized (58 active, 56 placebo); 53 and 52 assessed at 3 months. Unblinding and crossover offer at 3 months.

Participants and setting

114 adults at four Canadian sport-medicine and orthopaedic clinics (randomized November 2000–December 2002) with unilateral plantar fasciitis for more than 6 months, morning first-steps pain >5 on VAS and Roles and Maudsley 3–4, after failed NSAIDs and at least two other conservative treatments. Mean age 51.1 versus 48.8 years; women 40/58 versus 33/56; mean heel-pain history 31.3 versus 27.1 months.

Treatment protocol

One session with the Dornier Epos Ultra under ultrasound localization after a medial calcaneal nerve block: energy ramped over six levels, then about 3,500 shocks at 0.36 mJ/mm² (ED+) and 240 shocks/min, about 3,800 shocks and an approximated 1,300 mJ/mm² (ED+) in total. No sport or pain medication until 6 weeks.

Comparison

Placebo used the same procedure and nerve block, with a foam cushion on the therapy head blocking the shock waves. Both groups followed the same activity and medication restrictions.

What was measured

Primary: change from baseline to 3 months in VAS pain during the first minutes of walking in the morning. Secondary: success (>60% improvement), VAS in daily activity, sport and before bed, AOFAS ankle–hindfoot, Roles and Maudsley, SF-12, pressure-threshold tenderness, and adverse events. Blinded visits at 3–5 days, 6 weeks and 3 months.

Results and interpretation

Morning pain fell from 7.5 to 3.9 with active treatment and from 7.9 to 5.3 with placebo; the difference in change favoured active treatment (P=0.0124; Table 3 prints P<0.0001). Success was 25/53 (47%) versus 12/52 (23%), P=0.0099, and Roles and Maudsley excellent-good 23/53 versus 16/52, P=0.0121. Other VAS items, AOFAS and SF-12 did not differ significantly.

Harms and disclosures

Adverse events other than pain were few and, by Fisher tests, did not differ through 3 months: edema 3.5% versus 1.8%, paresthesia 1.8% versus 0, peripheral neuritis 1.8% versus 0 (resolved), back pain 1.8% versus 0 and pruritus in one placebo patient (both judged unrelated); pain after treatment 14% versus 27.3%. Pain during treatment was 79.3% versus 8.9%. Table 3 gives percentages without counts. All sites received research grants from Dornier MedTech America, the device maker.

Limitations

Patients often felt the active treatment (pain 79.3% versus 8.9%) and guessed their group more often, which may weaken blinding of a self-reported outcome. Analyses use observed patients despite an intention-to-treat claim, the primary P value differs between text and table, the abstract cites 6-week success data that are not shown, and blinded comparison stops at 3 months. The device maker funded all sites.

Applicability

Applies to adults with one painful heel for over six months after several conservative treatments, treated with this device, energy and nerve block. It does not test repeated sessions, other devices, radial shockwaves or effects beyond 3 months against placebo.

What stronger evidence needs

An independently funded trial with a sham that mimics treatment sensation, prespecified intention-to-treat analysis with confidence intervals, and blinded follow-up to 12 months.

THE ORIGINAL SOURCE

Read the original article.

Randomized, placebo-controlled, double-blind clinical trial evaluating the treatment of plantar fasciitis with an extracorporeal shockwave therapy (ESWT) device: a North American confirmatory study.

Kudo P, Dainty K, Clarfield M, Coughlin L, Lavoie P, Lebrun C. · Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2006

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →